<DOC>
	<DOCNO>NCT02403310</DOCNO>
	<brief_summary>The main purpose study determine safety combine selinexor daunorubicin cytarabine . The maximal tolerate dose ( MTD ) selinexor daunorubicin cytarabine also establish .</brief_summary>
	<brief_title>A Study Selinexor Combination With Daunorubicin Cytarabine Untreated AML</brief_title>
	<detailed_description>Induction Therapy - Dose escalation selinexor Daunorubicin cytarabine fix dos . Consolidation Phase - Patients complete remission ( CR ) complete remission incomplete count recovery ( CRi ) day ≤70 recover previous non- hematologic toxicity baseline grade ≤1 day ≤70 follow induction chemotherapy may go receive consolidation therapy 2 cycle . The consolidation treatment phase include two course therapy ( 28 day cycle ) follow : Daunorubicin 45mg/m^2/day ( day 1-2 ) Cytarabine 100mg/m^2/day ( continuous infusion day 1-5 ) Selinexor dose induction ( day 1,3,8,10 ) unless dose limit toxicity ( DLT ) dictate dose reduction . Selinexor give 2 hour prior daunorubicin day 1 . A second cycle consolidation therapy use dos administer , investigator discretion , 28 42 day follow initiation first consolidation treatment , peripheral blood count recover CR , CRi level , recovery non-hematologic toxicity baseline grade ≤1 . Dose escalation Selinexor occur consolidation phase . Maintenance Phase - Patients remain CR , CRi 2 cycle consolidation eligible allogeneic stem cell transplant eligible maintenance phase treatment recovery previous non-hematologic toxicity baseline grade ≤1 . Maintenance therapy consist : Selinexor dose induction day 1 8 21 day cycle . They continue maximum 12 month . Expansion Phase - Once MTD establish , expansion phase enroll additional 13 subject MTD good characterize safety profile tolerability .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Potential participant must newly diagnose , previously untreated acute myeloid leukemia ( AML ) ( exclude M3 ) ; Must adverserisk AML define poorrisk karyotype ( complex , monosomal know poor risk cytogenetic abnormality ) , poorrisk mutations/fusion gene know history antecedent hematologic disorder , treatment related AML , ≥60 year age ; Cytogenetics , FISH mutational analysis confirm adverse risk feature must do within 90 day prior enrollment . May undergone prior therapy AML hydroxyurea . However , patient antecedent myelodysplastic syndrome ( MDS ) , prior treatment hypomethylating agent therapy ( exception allogeneic stem cell transplant ) use treat MDS allow . Age ≥18 year Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Life expectancy great 2 month Must normal organ function Able willing adhere study visit schedule protocol requirement Baseline leave ventricular ejection fraction ( LVEF ) ≥ 50 % Women childbearing potential must negative serum urine pregnancy test sensitivity least 50 milliinternational unit per milliliter ( mIU ) mL ) within 10 day within 24 hour prior begin study treatment . Participants childbearing potential must practice recommend contraception . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Breastfeeding mother must agree discontinue nurse mother treat selinexor . Ability understand willingness sign write informed consent document Able swallow capsule evidence GI tract abnormality would alter absorption oral medication Prothrombin time ( PT ) partial thromboplastin time ( PTT ) ≤ 1.5 x upper limit normal ( ULN ) May receive investigational agent Documented central nervous system ( CNS ) involvement AML AML favorable risk cytogenetic abnormality include ( 15 ; 17 ) , ( 8 ; 21 ) inv ( 16 ) Potential participant blast phase chronic myeloid leukemia Major surgery within 2 week first dose study drug ; must recover effect surgery perform great 2 week prior White blood cell ( WBC ) count ≥50,000 hydroxyurea Predicted inability tolerate standard induction chemotherapy daunorubicin cytarabine Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement HIVpositive , receive combination antiretroviral therapy No malignancy addition AML currently require treatment exception basal cell squamous cell carcinoma skin , carcinoma situ cervix breast History allogeneic stem cell transplant MDS antecedent hematologic disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adverse-risk AML</keyword>
	<keyword>poor-risk karyotype</keyword>
	<keyword>cytogenetic abnormality</keyword>
	<keyword>poor-risk mutation</keyword>
	<keyword>antecedent hematologic disorder</keyword>
	<keyword>treatment relate AML</keyword>
</DOC>